

Palmar Hyperhidrosis - Pipeline Insight, 2021

<https://marketpublishers.com/r/P32F931037AEEN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P32F931037AEEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Palmar Hyperhidrosis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Palmar Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Palmar Hyperhidrosis Understanding

Palmar Hyperhidrosis: Overview

Palmar hyperhidrosis, or excessive hand sweating, is a common condition affecting 1-3% of the population. It usually starts in childhood or adolescence. Sweaty hands can significantly affect a person socially and emotionally. Many factors can contribute to the condition, including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. Palmar hyperhidrosis affects both hands equally and can range from mild clammy hands to severe sweating. It stops when sleep. The diagnosis is usually made based on a history of excessive sweating. No investigations are needed. Treatment will depend on how severe the sweating is and which previous treatments have been successful.

'Palmar Hyperhidrosis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmar Hyperhidrosis pipeline landscape is provided which includes the disease overview and Palmar Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Palmar Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmar Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Palmar Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmar Hyperhidrosis.

Palmar Hyperhidrosis Emerging Drugs Chapters

This segment of the Palmar Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Palmar Hyperhidrosis Emerging Drugs

AT-5214: Atacama Therapeutics

AT-5214 (dexmecamylamine) is the S-enantiomer of mecamylamine, a selective inhibitor of the acetylcholine nicotinic receptor. AT-5214 is thought to inhibit the sympathetic ganglion with lessened parasympathetic side effects. Currently, it is in Phase II stage of development to treat Palmar Hyperhidrosis.

Umeclidinium: GlaxoSmithKline

Umeclidinium is a Muscarinic receptor antagonist developed by GlaxoSmithKline. It is in Phase II stage of development to treat Palmar Hyperhidrosis.

Further product details are provided in the report.....

Palmar Hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Palmar Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Palmar Hyperhidrosis

There are approx. 3+ key companies which are developing the therapies for Palmar Hyperhidrosis. The companies which have their Palmar Hyperhidrosis drug candidates in the most advanced stage, i.e. phase II include, Atacama Therapeutics.

Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Palmar Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under

various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmar Hyperhidrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmar Hyperhidrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmar Hyperhidrosis drugs.

Palmar Hyperhidrosis Report Insights

Palmar Hyperhidrosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Palmar Hyperhidrosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Palmar Hyperhidrosis drugs?

How many Palmar Hyperhidrosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

the treatment of Palmar Hyperhidrosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmar Hyperhidrosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Palmar Hyperhidrosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Atacama Therapeutics

GlaxoSmithKline

Brickell Biotech, Inc.

Candesant Biomedical

Key Products

AT-5214

Umeclidinium

Sofpironium bromide

Contents

Introduction

Executive Summary

Palmar Hyperhidrosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Palmar Hyperhidrosis – DelveInsight's Analytical Perspective

Mid Stage Products (Phase II)

Comparative Analysis

AT-5214: Atacama Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Palmar Hyperhidrosis Key Companies

Palmar Hyperhidrosis Key Products

Palmar Hyperhidrosis- Unmet Needs

Palmar Hyperhidrosis- Market Drivers and Barriers
Palmar Hyperhidrosis- Future Perspectives and Conclusion
Palmar Hyperhidrosis Analyst Views
Palmar Hyperhidrosis Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Palmar Hyperhidrosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Palmar Hyperhidrosis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Palmar Hyperhidrosis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P32F931037AEEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P32F931037AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970